Clinical Report: Utilization of Liquid Biopsy Techniques in Childhood Acute Lymphoblastic Leukemia (ALL)
Overview
This review discusses the application of liquid biopsy technologies in pediatric acute lymphoblastic leukemia (ALL), focusing on circulating tumor DNA, microRNAs, and extracellular vesicles.
Background
Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric malignancy, with relapse being a significant cause of treatment failure. Liquid biopsy offers a minimally invasive method for real-time monitoring and assessment of measurable residual disease (MRD).
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Liquid biopsy technologies include circulating tumor DNA (ctDNA), circulating microRNAs (miRNAs), and extracellular vesicles (EVs).
These technologies can aid in diagnosis and MRD assessment in pediatric ALL.
Challenges in pediatric applications include limited blood volume and pre-analytical variability.
Bone marrow evaluation remains the gold standard for diagnosis and MRD monitoring in pediatric ALL.
Continued validation in large pediatric cohorts is necessary for clinical implementation.
Clinical Implications
The integration of liquid biopsy techniques in pediatric ALL requires careful consideration of limitations and the need for further validation.
Conclusion
Liquid biopsy represents an advancement in the management of pediatric ALL, but its clinical application requires further research.
